Outcome at 4.5 years after dextrose gel treatment of hypoglycaemia: follow-up of the Sugar Babies randomised trial
Deborah L Harris,Greg D Gamble,Jane E Harding,CHYLD Study Group,Jane Harding,Jane M Alsweiler,Trecia A Wouldes,Gavin T L Brown,Christopher J D McKinlay,Benjamin Thompson,J Geoffrey Chase,Judith Ansell,Anne Jaquiery,Kelly Jones,Sapphire Martin,Christina McQuoid,Jenny Rogers,Heather Stewart,Anna Timmings,Anna Tottman,Kate Williamson,Arun Nair,Alexandra Wallace,Phil Weston,Nicola Austin,Jeremy Armishaw,Nicola Webster,Ross Haslam,Pat Ashwood,Lex Doyle,Kate Callanan,Ian Wright,Jessica Brosnahan,Ellen Campbell,Coila Bevan,Tineke Crawford,Kelly Fredell,Kate Sommers,Claire Hahnhaussen,Safayet Hossin,Karen Frost,Grace McKnight,Janine Paynter,Jess Wilson,Rebecca Young,Anna Gsell,Aaron Le Compte,Matthew Signal,Yannah Jiang,Tzu-Ying Sandy Yu
DOI: https://doi.org/10.1136/archdischild-2022-324148
Abstract:Objective: Dextrose gel is used to treat neonatal hypoglycaemia, but later effects are unknown. Design and setting: Follow-up of participants in a randomised trial recruited in a tertiary centre and assessed in a research clinic. Patients: Children who were hypoglycaemic (<2.6 mmol/L) recruited to the Sugar Babies Study (>35 weeks, <48 hours old) and randomised to treatment with 40% dextrose or placebo gel. Interventions: Assessment of neurological status, cognitive ability (Weschler Preschool and Primary Scale of Intelligence), executive function (five tasks), motor function (Movement Assessment Battery for Children-2 (MABC-2)), vision, visual processing (Beery-Buktenica Development Test of Visual Motor Integration (Beery VMI) and motion coherence thresholds) and growth at 2 years. Main outcome measures: Neurosensory impairment (cerebral palsy; visual impairment; deafness; intelligence quotient <85; Beery VMI <85; MABC-2 score <15th centile; low performance on executive function or motion coherence). Results: Of 237 babies randomised, 185 (78%) were assessed; 96 randomised to dextrose and 89 to placebo gel. Neurosensory impairment was similar in both groups (dextrose 36/96 (38%) vs placebo 34/87 (39%), relative risk 0.96, 95% CI 0.66 to 1.34, p=0.83). Secondary outcomes were also similar, except children randomised to dextrose had worse visual processing scores (mean (SD) 94.5 (15.9) vs 99.8 (15.9), p=0.02) but no differences in the proportion with visual processing scores <85 or other visual test scores. Children randomised to dextrose gel were taller (z-scores 0.18 (0.97) vs -0.17 (1.01), p=0.001) and heavier (0.57 (1.07) vs 0.29 (0.92), p=0.01). Conclusions: Treatment of neonatal hypoglycaemia (<2.6 mol/L) with dextrose gel does not alter neurosensory impairment at 4.5 years. However, further assessment of visual processing and growth may be warranted. Trial registration number: ACTRN1260800062392.